374794-89-5

Basic information

• Product Name: 1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate
• Synonyms: 1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate;tert-butyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate;1-Oxa-8-azaspiro[4.5]decane-8-carboxylicacid
• CAS NO: 374794-89-5
• Molecular Formula: C₁₃H₂₃NO₃
• Molecular Weight: 241.33
• Product Categories: API intermediates
• Mol File: 374794-89-5.mol

Chemical Properties

• Boiling Point: 333.508°C at 760 mmHg
• Flash Point: 155.501°C
• Appearance: /
• Density: 1.08
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.502
• CAS DataBase Reference: 1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate(374794-89-5)
• EPA Substance Registry System: 1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate(374794-89-5)

Safety Data

• Hazardous Substances Data: 374794-89-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate is used as a research compound for its potential pharmacological properties. Its unique spiro structure makes it a valuable candidate for the development of new pharmaceuticals with diverse biological activities.
Used in Central Nervous System Disorders:
1,1-Dimethylethyl 1-oxa-8-azaspiro[4.5]decane-8-carboxylate is used as a potential therapeutic agent for central nervous system disorders. Its potential biological activity and therapeutic applications are currently being explored through further research and studies.

InChI:InChI=1/C13H23NO3/c1-12(2,3)17-11(15)14-8-6-13(7-9-14)5-4-10-16-13/h4-10H2,1-3H3

Upstream product

• 1192122-45-4 tert-butyl 4-hydroxy-4-[3-[(methylsulfonyl)oxy]propyi]piperidine-1-carboxylate 
• 1192122-44-3 tert-butyl 4-[3-[[tert-butyl(dimethyl)silyl]oxy]propyl]-4-hydroxypiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 374794-88-4 tert-butyl 4-hydroxy-4-(3-hydroxypropyl)piperidine-1-carboxylate 
• 301226-27-7 tert-butyl 2-oxo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate 
• 374794-91-9 1,1-dimethylethyl 4-(3-ethoxy-3-oxoprop-1-yl)-4-hydroxy-1-piperidinecarboxylate 
• 374794-90-8 1,1-dimethylethyl 4-(3-ethoxy-3-oxo-1-propynyl)-4-hydroxy-1-piperidinecarboxylate 

Downstream Products

• 3970-79-4 1-oxa-8-aza-sprio[4,5]decane hydrochloride 
• 176-92-1 4-dioxa-8-azaspiro[4.5]decane 

Relevant articles and documents

SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS

This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS

The present invention relates to the compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and W are as defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

4,4-Disubstituted cyclohexylamine NK1 receptor antagonists II

A series of novel 4,4-disubstituted cyclohexylamines as NK1 receptor antagonists is described: modifications to the amine moiety retain NK1 receptor binding affinity whilst disrupting IKr affinity.